Wealth Alliance Advisory Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.89M Sell
11,481
-3,156
-22% -$679K 0.42% 47
2026
Q1
$3.18M Buy
14,637
+1,198
+9% +$266K 0.5% 40
2025
Q4
$3.07M Buy
13,439
+31
+0.2% +$7.06K 0.53% 38
2025
Q3
$3.1M Buy
13,408
+247
+2% +$50.3K 0.56% 39
2025
Q2
$2.44M Buy
13,161
+3,047
+30% +$566K 0.47% 42
2025
Q1
$2.12M Buy
10,114
+838
+9% +$163K 0.44% 44
2024
Q4
$1.65M Buy
9,276
+1,656
+22% +$304K 0.35% 52
2024
Q3
$1.5M Buy
7,620
+288
+4% +$53.8K 0.32% 57
2024
Q2
$1.26M Sell
7,332
-370
-5% -$61.3K 0.28% 62
2024
Q1
$1.4M Sell
7,702
-207
-3% -$35.7K 0.33% 52
2023
Q4
$1.23M Buy
7,909
+6
+0.1% +$875 0.32% 50
2023
Q3
$1.18M Sell
7,903
-4,039
-34% -$593K 0.35% 48
2023
Q2
$1.61M Sell
11,942
-376
-3% -$55.1K 0.57% 33
2023
Q1
$1.96M Buy
12,318
+2,538
+26% +$388K 0.73% 26
2022
Q4
$1.58M Buy
9,780
+224
+2% +$34.3K 0.6% 33
2022
Q3
$1.28M Buy
9,556
+2,382
+33% +$342K 0.57% 36
2022
Q2
$1.1M Buy
7,174
+532
+8% +$81.3K 0.52% 36
2022
Q1
$1.08M Buy
6,642
+1,693
+34% +$246K 0.47% 39
2021
Q4
$670K Buy
4,949
+272
+6% +$32.1K 0.29% 63
2021
Q3
$505K Buy
4,677
+563
+14% +$64.3K 0.25% 69
2021
Q2
$463K Hold
4,114
0.23% 75
2021
Q1
$445K Sell
4,114
-300
-7% -$32.1K 0.23% 73
2020
Q4
$473K Hold
4,414
0.26% 67
2020
Q3
$387K Sell
4,414
-318
-7% -$29.9K 0.23% 67
2020
Q2
$465K Buy
4,732
+174
+4% +$15.3K 0.29% 59
2020
Q1
$347K Buy
4,558
+636
+16% +$54.2K 0.27% 67
2019
Q4
$347K Buy
3,922
+18
+0.5% +$1.49K 0.2% 80
2019
Q3
$287K Sell
3,904
-122
-3% -$8.36K 0.18% 85
2019
Q2
$283K Buy
4,026
+100
+3% +$7.86K 0.17% 91
2019
Q1
$306K Buy
3,926
+131
+3% +$10.7K 0.2% 82
2018
Q4
$350K Buy
3,795
+1,013
+36% +$89.1K 0.26% 65
2018
Q3
$263K Buy
2,782
+1
+0% +$95 0.13% 110
2018
Q2
$258K Sell
2,781
-1
-0% -$98 0.14% 106
2018
Q1
$263K Buy
+2,782
New +$306K 0.15% 92

Other funds holding ABBV

Wealth Alliance Advisory Group's ABBV Position: Q2 2026 in Review

Wealth Alliance Advisory Group reduced its AbbVie (ABBV) stake by 22% in Q2 2026, selling an estimated $679K and leaving 11,481 shares worth $2.89M. The position accounts for 0.42% of the portfolio, ranked #47.

Wealth Alliance Advisory Group first reported a position in ABBV in Q1 2018 and has held it in 34 quarters since. The position peaked at $3.18M in Q1 2026. 2,119 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Wealth Alliance Advisory Group held 11,481 shares of AbbVie worth $2.89M as of Q2 2026.
  • Wealth Alliance Advisory Group sold 3,156 AbbVie shares in Q2 2026, an estimated $679K.
  • AbbVie made up 0.42% of Wealth Alliance Advisory Group's portfolio in Q2 2026, its #47 holding.
  • Wealth Alliance Advisory Group first reported a position in AbbVie in Q1 2018 and has held it in 34 quarters since.
  • Wealth Alliance Advisory Group's AbbVie position peaked at $3.18M in Q1 2026.
  • 2,119 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Wealth Alliance Advisory Group's 13F filing for Q2 2026, filed 23 Jul 2026.